56% mean improvement in Total Symptom Score (TSS) at 24 weeks with 76% of patients achieving at least a 50% reduction in TSS
89% of patients had >50% decrease in serum tryptase by four weeks of treatment and 95% of patients with elevated baseline tryptase achieved serum tryptase levels 50% reduction from baseline in MS2D2 Total Symptom Score (TSS) with 88% of patients exceeding 30% reduction from baseline after 24 weeks
At 24 weeks of treatment, 31% of patients have already reduced or discontinued best supportive care (BSC) medications.
Pharmacodynamic DataBezuclastinib showed rapid, deep, and sustained reductions in serum tryptase over the course of 24 weeks of treatment including:
- 89% of patients had >50% decrease in serum tryptase levels by four weeks of treatment
- 95% of patients with baseline tryptase ≥20ng/mL achieved 11.4ng/ml achieved